1. Scrip

US Fast Track Boosts Sumitomo's Oncology Pivot

 
• By Lisa Takagi

Sumitomo’s novel AML candidate has shown early clinical promise and been granted US Fast Track status for a form of AML, which looks set to aid the Japanese firm's strategic shift to oncology following recent CNS setbacks. 

Sumitomo is planning to start a pivotal study for DSP-3665 by the end of its fiscal year 2024.
Sumitomo plans pivotal study for leukemia candidate • Source: Shutterstock

A US fast track designation for Sumitomo Pharma Co., Ltd.'s acute myeloid leukemia (AML) candidate has given the Japanese company's key oncology pipeline a boost as it looks to overcome multiple challenges in its mainstay CNS business. 

DSP-5336, an inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, recently received Fast Track designation from the US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 
• By Anju Ghangurde

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.